Population | Specific conditions |
Patients who are severely immunocompromised (regardless of severity of mpox at time of presentation) |
|
Persons with active skin conditions placing the person at higher risk for disseminated infection |
|
Pregnant or lactating individuals (regardless of severity of mpox at time of presentation) | |
Persons <18 years of age (regardless of severity of mpox at time of presentation) | |
Patients with protracted or life-threatening manifestations of mpox at presentation |
|
In the United States, tecovirimat is an investigational agent and is not commercially available. These patient groups may meet criteria for the open label arm of the Study of Tecovirimat for Mpox (STOMP) Trial. They also meet criteria to receive the drug outside of a clinical trial though the CDC's Expanded access investigational new drug (EA-IND) protocol.
Clinicians can contact the CDC Clinical Consultation Team by email ([email protected]) or by phone (770-488-7100) for urgent clinical situations.Adapted from: Tecovirimat (TPOXX) for treatment of mpox. Centers for Disease Control and Prevention. https://www.cdc.gov/poxvirus/mpox/clinicians/tecovirimat-ea-ind.html (Accessed on July 30, 2024).